Choroideremia is a monogenic X-linked recessive chorioretinal disease linked to pathogenic variants in the CHM gene. These variants are commonly base-pair changes, frameshifts, or large deletions. However, a few rare or unusual events comprising large duplications, a retrotransposon insertion, a pseudo-exon activation, and two c-98 promoter substitutions have also been described. Following an exhaustive molecular diagnosis, we identified and characterized three novel atypical disease-causing variants in three unrelated male patients. One is a first-ever reported Alu insertion within CHM and the other two are nucleotide substitutions, c.-90C>G and c.-108A>G, affecting highly conserved promoter positions. RNA analysis combined with western blot and functional assays of patient cells established the pathogenicity of the Alu insertion and the c.-90C>G alteration. Furthermore, luciferase reporter assays suggested a CHM transcription defect associated with the c.-90C>G and c.-108A>G variants. These findings broaden our knowledge of the mutational spectrum and the transcriptional regulation of the CHM gene.
CHM. The clinical diagnosis of CHM was established for the three probands. Two of the patients (herein referred to as CHM8 and CHM9; 51 and 43 years old, respectively) were considered as symptomatically mild with a relatively large preserved central islet, whereas the third (CHM10; 45 years old) presented with a classical CHM phenotype.
Genomic analysis of patient CHM8 detected a polymerase chain reaction (PCR) product for exon 7, which was larger than the expected 318 bp ( Figure 1A) . Bidirectional sequencing of this aberrant product detected an ∼280 bp insertion in exon 7 at c.884 flanked by a 15-bp direct repeat sequence generated by a target site duplication ( Figure 1B) . The exact length of this insertion could not be determined because of the presence of a ≥40-(A) stretch at its 5 ′ -end leading to polymerase slippage events during the amplification process. A multialignment of the inserted sequence with an Alu reference sequence was performed using the Dfam database (Hubley et al., 2016) . This confirmed the short interspersed nuclear element (SINE) origin of the inserted sequence and its close relation to the AluYa5 family. The inserted sequence (NM_000390.2: c.884_885ins[AluYa5;870_884]), situated in the sense orientation with respect to the CHM coding sequence, differed from the AluYa5 subfamily consensus by a 38 bp 5 ′truncated end and a single base pair substitution (C>T) at position 108 ( Figure 1C ).
In order to better characterize this insertion, transcript analysis was performed on patient CHM8 and a control individual. In CHM8, sequencing of reverse transcription (RT) PCR products, amplified from RNA isolated from peripheral blood samples and cultured skin fibroblasts, identified two aberrant splicing patterns. These resulted from the skipping of the last 56 nucleotides of exon 7 followed by an insertion of either the first 29 (r.884_940delins29) or 61 nucleotides (r.884_940delins61) of the Alu element due to the use of two different cryptic donor splice sites located within this sequence ( Figure 1D ). An open-reading frame was preserved in the smaller transcript, whereas, in the larger one, a premature termination codon appeared in exon 8; abnormal REP1 proteins of 644 and 325 amino acids were predicted to be produced, respectively. As depicted in Figure 1E , quantitative RT-PCR (qRT-PCR; Supporting Information Methods) experiments performed on mRNA isolated from cultured fibroblasts detected a significantly sixfold lower level of all CHM transcripts in the patient's cells compared to control cells (P < 0.05) suggesting a greater instability or weaker production. Western blot analysis using an antibody directed against the C-terminal region of REP1 detected residual expression (3.6% of wild type) that likely corresponded to the altered 644-amino acid REP1 ( Figure 1F ). Finally, using an in vitro biotinylated prenylation assay, which evaluates the size of the unprenylated cytosolic Rab pool (Supporting Information Methods), we showed a significant 10-fold increase in biotinylated Rab levels ( Figure 1G PCR-based sequencing strategy was performed for patient CHM10 but failed to identify a pathogenic event at the genomic level. In order to test for the presence of deep intronic or promoter variations, we screened the whole CHM gene and its upstream noncoding region by next-generation sequencing (NGS) technology. With this new approach, using the methodology described in Liquori et al. (2016) , no intronic variants predicted to affect splicing were observed but we detected a c.-108A>G variant that was not listed in dbSNP150 and gnomAD 2.0.2. This variant was situated in the forward primer used initially to amplify exon 1 and hence escaped detection by in the absence of a promoter sequence, background luciferase levels were 0.05 ± 0.005. Lastly, as we had access to the skin fibroblasts of patient CHM9, we assayed the molecular and biochemical defects in these cells. We did not detect a CHM transcript ( Figure 2C ) or REP1 expression ( Figure 2D ). Consistently, we detected significantly increased (3.5-fold; P < 0.05) biotinylated Rab levels (Figure 2E,F) indicative of a prenylation defect. Taken together, these results definitively confirmed the pathogenicity of the c.-90C>G variant and strongly inferred that of the c.-108A>G alteration.
To summarize, we identified and demonstrated the pathogenicity of three atypical variants leading to CHM: the first-ever reported Alu insertion within the CHM gene and two novel single-base substitutions in the CHM promoter. These are loss-of-function mutations that, as confirmed for two of them, result in reduced protein expression and underprenylation of Rab GTPases, which is characteristic of CHM. L1 or SINE insertion events that lead to disease by disrupting a coding region or altering the splicing process remain rare. Although these events are largely random, the X chromosome appears particularly prone to disease-causing retrotransposon insertions (Hancks & The onset and degree of visual loss are variable among CHM patients, even within the same family, and cross-analyses of clinical symptoms and genotypes failed to show any correlation that can explain this variability (Freund, Sergeev, & MacDonald, 2016; Sanchez-Alcudia et al., 2016; Simunovic et al., 2016) . Our results also do not fit a genotype-phenotype correlation, for example, the c.-90C>G substitution leads to a total absence of REP1 in a patient presenting with mild CHM, whereas the c.-108A>G variant is carried by a patient presenting with a typical phenotype.
In conclusion, this study describing the characterization of three novel CHM pathogenic alterations extends the mutational spectrum of CHM, increases our understanding of the transcriptional regulation of CHM, and reiterates the importance of exhaustive molecular screening.
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